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Particular CSF sphingolipid patterns 
identify iNPH and AD patients
Enrica Torretta1, Beatrice Arosio2,3, Pietro Barbacini1, Martina Casati2, Daniele Capitanio1, 
Roberta Mancuso3, Daniela Mari2, Matteo Cesari2,3, Mario Clerici4,5 & Cecilia Gelfi  1,6
Idiopathic normal pressure hydrocephalus (iNPH) is characterized by reversible neurological symptoms 
due to an impairment in cerebrospinal fluid (CSF) clearance. In these patients, cognitive functions are 
severely impaired, with a scenario similar to Alzheimer’s disease (AD), making the differential diagnosis 
difficult and highlighting the need of new markers. We analyzed the composition of sphingolipids (SLs) 
in serum, by combining a single phase extraction with a high-performance thin-layer chromatography 
(HPTLC) primuline-profiling, and, in CSF, by MALDI profiling and LC-MS. Ceramides and sphingomyelins 
(SMs) were similar in serum of iNPH and AD patients compared to healthy controls, whereas, in CSF, 
MALDI profiling indicated that: 1) SM C24:1 is significantly decreased in AD compared to iNPH patients 
and controls (Kruskal-Wallis p-value < 0.00001); 2) phosphatidylcholine (PC) 36:2 is increased in iNPH 
patients (p-value < 0.001). LC-MS identified an increasing trend of Cer C24:0 and of a set of SMs in 
patients with AD, a significant decrease of sphingosine-1-phosphate (S1P) (t-test p-value 0.0325) and 
an increase of glucosylceramide (GlcCer) C24:0 (p-value 0.0037) in AD compared to iNPH patients. In 
conclusion CSF PC 36:2, SM C24:1, S1P, and GlcCer can contribute to improve the differential diagnosis 
of patients with iNPH or AD and foster preventive therapeutic strategies in the early phase of the 
disease.
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized at the onset by memory loss, followed 
by spatial disorientation and wandering, difficulty in communication, mood changes, and behavioral disorders 
at advanced phases. The prevalence of AD is continuously increasing, due to earlier diagnosis and increased life 
expectancy. It is estimated a number of 13.2 million patients by the year 20501, obviously representing a major 
challenge for the sustainability of healthcare systems.
The lack of knowledge about the pathophysiological mechanisms of the disease and the absence of biomarkers 
able to predict the evolution of the disease from the prodromal phases to the overt manifested AD, substan-
tially affect preventive and therapeutic strategies. Current FDA-approved drugs (e.g. cholinesterase inhibitors, 
NMDA-receptor agonists) are only symptomatic and not disease-modifiers.
AD diagnosis is currently based on combination of information coming from the patient’s disease history, 
the assessment of the cognitive function, and neuroimaging (CT, MRI and PET)2. The measurement of levels of 
amyloid-β (Aβ42), total-tau (t-tau), and phospho-tau181 (p-tau) in cerebrospinal fluid (CSF) can support the dif-
ferential diagnosis of AD, and support the prediction of those individuals with mild cognitive impairment (MCI) 
potentially converting to AD in the future3–5.
Idiopathic normal pressure hydrocephalus (iNPH) is a disease characterized by reversible neurological symp-
toms due to impairment of CSF clearance6,7. Patients show a severely cognitive impaired function, often difficult 
to differentiate from AD8. Initially, the disease was described as a triad of symptoms: cognitive impairment, 
urine incontinence and gait disturbance9. iNPH symptoms can be alleviated by shunt surgery10. Notably, in 18% 
to 42% of cases, AD represents a comorbidity of iNPH11,12. It is noteworthy that AD and iNPH patients present 
similar clinical features and molecular characteristics13, including amyloid deposition14,15 and t-tau and p-tau 
dysregulation. However, quantitative results of t-tau and p-tau on iNPH patients are contradictory, due to high 
interindividual variability indicating the need of other markers for improving the differential diagnosis16–20 and 
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to predict the evolution toward cognitive impairment (CI). Starting treatments in the early phase will counteract 
the stabilization of CI in iNPH or contribute to slow it down in AD.
In a previous study21, we described the differential protein profile and the APOA1 proteoform composition 
in CSF of iNPH and AD patients; results showed that the CSF profiling of low abundant low molecular weight 
proteins of iNPH was similar to that of healthy controls, indicating that alterations in CSF proteins are typical of 
AD patients.
To shed light on the pathogenesis of AD and iNPH we analyzed the lipidome and, specifically, the composition 
of sphingolipids (SLs) in these patients. SLs are structural components of the plasma membrane involved in the 
regulation of membrane fluidity, intercellular communication, signal transduction and cell activation. Alterations 
in the metabolism of these lipids is known to be correlated with neurodegenerative disease, including AD, and 
changes in SLs level were recently described in MCI and AD patients22,23. However, comparative studies explor-
ing levels of circulatory SLs in a transient state of cognitive impairment such in patients with iNPH are lacking. 
Herein, we investigated SLs flux in iNPH and AD patients by combining a single phase extraction method with a 
HPTLC primuline-profiling in serum and by MALDI profiling and LC-MS in CSF.
Results
Serum and CSF samples were collected from 10 patients affected by iNPH (M/F-5/5, age 85 ± 9.6), and 16 patients 
with AD disease (M/F-7/9, age 76 ± 3.8). CSF samples from 10 control subjects with no history of neurogical 
disorders (M/F- 6/4, age 75 ± 4.7) were also analyzed. Concentration of free Aβ42, t-tau and p-tau were meas-
ured in CSF. Free Aβ42 values were pathological for patients with AD (392 pg/mL) and normal for healthy sub-
jects (1082 pg/mL) and patients affected by iNPH (790 pg/mL). The same was observed for t-Tau (774 pg/mL in 
patients with AD, 103 pg/mL in healthy subjects and 157 pg/mL in patients with iNPH) and for p-Tau (84 pg/mL 
for patients with AD and 26 pg/mL for healthy subjects and patients with iNPH). Patients’ description is shown 
in Table 1 and in Table S1.
Sphingolipid profiling in serum. Differences in the sphingolipid profiles in serum of control subjects and 
of iNPH and AD patients were investigated by HPTLC-densitometry and FDIC (fluorescence detection by inten-
sity changes) emission after primuline staining.
After extraction, sphingolipids from 10 controls, 10 iNPH and 16 AD sera were separated on HPTLC plates 
and SL bands were compared by densitometry.
From primuline stained HPTLC plates, bands corresponding to Cers and SMs were identified by Rf compar-
ison with standards, carrying a variation coefficient (CV) of 6–7%; bands with Rf = 0.923, Rf = 0.858, Rf = 0.176 
and Rf = 0.152 were respectively attributed to long chain Cers, short chain Cers, long chain SMs and short chain 
SMs.
Primuline quantitative staining revealed a statistically significant increase of long and short chains Cers 
(Kruskal-Wallis p-value < 0.001) in patients with iNPH and with AD compared to controls. Long chain SMs were 
unchanged whereas short chain SMs increased both in iNPH and AD patients (Kruskal-Wallis p-value < 0.001) 
compared to controls. No significant changes were detected between iNPH and AD patients in blood (Fig. 1).
CSF MALDI profiling analysis. To get better insights into the differences of the sphingolipid profiles related 
to the neurodegenerative process compared to controls, lipids were extracted from CSF of AD and iNPH patients 
and from age-matched control subjects. The low abundance of SLs in CSF hampered their detection by prim-
uline staining, so CSF extracted organic phases were loaded with DHB matrix on an Anchorchip MALDI target 
for spectra acquisition and MALDI profiling analysis. Statistical analysis performed by ClinProTools software 
detected 6 “best separating peaks” (Kruskal-Wallis p-value < 0.01, with CV < 20%) (Table 2). To determine which 
peak differs in which groups, a pairwise comparison was performed. A recent study on the same group of patients 
demonstrate that the protein/peptide CSF profiles of healthy controls and of patients with iNPH didn’t show any 
statistically significant difference21. Same results were obtained when MALDI profiling of the lipid organic phases 
were achieved from controls and iNPH patients, further supporting the use of these samples in comparative 
studies of AD patients. Conversely, comparing organic phases from AD, iNPH patients and controls, several 
differences were observed, particularly peaks at 766.58 m/z and at 835.68 m/z were statistically decreased in AD 
patients compared to control subjects (with AUC values of 0.910156 and 0.953125, respectively), and to iNPH 
patients (Fig. 2A,F). Interestingly, peaks at 794.61 m/z, 796.59 m/z, 808.61 m/z and 830.61 m/z were statistically 
changed between iNPH and AD patients, only (Fig. 2B–E). AUC values of best separating peaks for patients with 
iNPH vs AD comparison are shown in Table 3. All peaks were underexpressed in patients with AD.
Healthy subjects, 
N = 10 (M = 6/F = 4)
iNPH patients, 
N = 10 (M = 5, F = 5)
AD patients,  
N = 16 (M = 7, F = 9)
Age, years (median, min-max, standard deviation) 75 (68–84) ± 4.7 85 (70–100) ± 9.6 76 (70–82) ± 3.8
Aβ, pg/mL (median, min-max, s.d.) 1082 (453–1515) ± 467 790 (718–1248) ± 267 392 (226–563) ± 96
Tau, pg/mL (median, min-max, s.d.) 103 (49–507) ± 160 157 (75–284) ± 73.4 774 (208–1420) ± 394
p-Tau, pg/mL (median, min-max, s.d.) 26 (7–80) ± 24 26 (15–42) ± 9.2 84 (28–136) ± 31.7
MMSE // 28 (17–29) ± 3.9 22 (13–27) ± 4.3
Table 1. Participants’ characteristics.
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Best separating peaks identification. The identification of best separating peaks was performed by 
MALDI-MS/MS. Based on the m/z ratio of parent ion and on fragment ions assignment, the peak at 835.68 m/z 
was identified as a sphingomyelin (SM d18:1 C24:1 [M + Na]+) (Fig. 1S). To validate this identification, the 
organic phase was submitted to alkaline hydrolysis, which removes all phospholipids except sphingomyelin. The 
latter is characterized by an amide group resistant to the hydroxide nucleophilic attack. Spectra of hydrolized 
sample achieved by MALDI identified a signal at 835.68 m/z confirming sphingomyelin identification (Fig. 2S).
Other differentially changed peaks were identified as phosphatidylcholines (PCs) (Table 4). The peak at 
808.61 m/z was attributed to PC 36:2 [M + Na]+ through the NIST MS Search v 2.2 software (Fig. 3S), whereas for 
peaks at 766.58 m/z and at 796.59 m/z, the software provided multiple structures, as the m/z peak ratio overlaps 
with different phosphatidylcholines (Fig. 4S).
LC-MS analysis. It is well known that MALDI profiling cannot provide the detection of all SL species due to 
the ion suppression caused by phospholipids or by peaks generated by the DHB matrix. To get better insights into 
the sphingolipidome of CSF in patients with iNPH and AD, 3 sub-pools per group were created and analysed by 
LC-MS. The sub-pooling has been largely adopted in proteomic studies to reduce the variance among biological 
groups increasing the power to detect more significant changes when few samples are available and the variance 
is high. In the present study we adopted the same approach to enlarge the set of differentially expressed SL species 
due to the wide inter individual variability of serum sphingolipidome taking into account results from the well 
standardized primuline staining shown in Fig. 1 and considering the absence of any reference data.
Quantitation of SMs, dhSMs and Cer (Fig. 3A–C) confirmed the increasing trend observed for SMs (except 
for SM C24:1) and dhSM, although not statistically significant, together with an increasing trend of Cer C24:0 in 
AD compared to iNPH patients. Sphingosine-1-phosphate (S1P) (Fig. 3D) was statistically decreased in CSF of 
AD compared to iNPH patients (t-test p-value 0.0325), whereas glucosylceramide C24:0 (Fig. 3E) was statistically 
increased in AD compared to iNPH patients (t-test p-value 0.0037).
Western blot analysis. Data from LC-MS and MALDI profiling analysis showed differences between 
patients with AD and iNPH, and provided a picture of the complexity of metabolic pathways that led to sphin-
golipidomics differences. To determine and validate, at least indirectly, changes observed in the sphingolipid 
profiles of our patients, the sphingomyelinase and ceramidase, involved in the metabolic pathway of SM and Cer, 
levels were assessed by immunoblotting in CSF of AD and iNPH patients. Quantitation of nSMase (neutral sphin-
gomyelinase) and ASM (acid sphingomyelinase) (Fig. 4) revealed a decreasing trend, although not statistically 
0
1
2
3
4
5
6
long-chain 
Cers
short-chain
Cers
long-chain
SMs
short-chain
SMs
controls
iNPH
AD
*
*
*
*
* *
O
pt
ic
al
 D
en
si
ty
 (A
U
)
Figure 1. Comparison of ceramides and SMs circulating levels in sera from controls (n = 10), iNPH (n = 10) 
and AD (n = 16) patients by primuline/HPTLC densitometry. Long and short chain Cers were statistically 
increased (Kruskal-Wallis p-value < 0.001) in sera from iNPH (Dunn’s test p-value < 0.05) and AD (Dunn’s test 
p-value < 0.05) compared to control subjects. Long chain SMs were unchanged whereas short chain SMs were 
statistically higher (Kruskal-Wallis p-value < 0.001) in sera from iNPH (Dunn’s test p-value < 0.05) and AD 
(Dunn’s test p-value < 0.05) compared to controls.
Peak Mass Kruskal-Wallis P-Value
766.576 0.000059
794.611 0.000212
796.591 0.00261
808.613 0.000102
830.606 0.000372
835.684 0.00000355
Table 2. List of ‘best separating’ peaks (Kruskal-Wallis p-value < 0.01, CV < 20%) obtained through 
sphingolipid MALDI profiling analysis on CSF samples taken from control subjects and iNPH and AD patients.
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Figure 2. Close-up of ClinProTools average spectra for control subjects (red), iNPH (green) and AD patients 
(blue), showing best separating peaks. Box-plots are shown for each peak. CSF samples were extracted with 
chloroform/methanol and lipid fractions were spotted onto the AnchorChip target in four replicates; spectra 
have been acquired in reflectron positive mode in the m/z range 200–2000. No changed peaks was detected in 
the pairwise comparison of control subjects versus iNPH patients. Peaks at 766.57 m/z (A) and at 835.68 m/z 
(F) were statistically changed between control subjects and AD patients and between iNPH and AD patients. 
Conversely, peaks at 794.61 m/z (B), 796.59 m/z (C), 808.61 m/z (D) and 830.61 m/z (E) statistically differ 
between iNPH and AD patients, only.
Peak Mass AUC Value (iNPH vs AD)
766.576 0.929688
794.611 0.900391
796.591 0.849609
808.613 0.935547
830.606 0.902344
835.684 0.974609
Table 3. AUC values of best separating peaks in the pairwise comparison of iNPH vs AD.
m/z theorical m/z (*)
Identification/Proposed 
structures
835.684 835.666 SM d18:1 C24:1 [M + Na]+
808.613 808.583 PC 36:2 [M + Na]+
766.576 766.551 PC(O-16:0) [M + H]+
PC 35:5 [M + H]+
PC 33:2 [M+Na]+
796.591 796.554 PC 36:8 [M+Na]+
PC 37:4 [M+H]+
PC 35:1 [M+Na]+
Table 4. Proposed structures for best separating peaks at 835.684, 808.613, 766.576, 769.591 m/z.
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significant, in AD patients compared to iNPH, whereas, Anti-Ceramidase antibody (anti-ASAH2) was tested on 
the same sub-pools but ceramidase was, in our hands, undetectable in CSF samples.
Figure 5 provides an overview of results characterizing the CSF SLs profiling of iNPH and AD patients. PC 
36:2 and SM C24:1 were significantly decreased in AD compared to iNPH patients whereas total SMs tended to 
increase; nSMase and ASM revealed a decreasing trend, whereas Cer C24:0 tended to augment. Sphingosine-
1-phosphate (S1P) was significantly reduced in AD compared to iNPH patients whereas glucosylceramide 
(GlcCer) C24:0 increased.
0
2
4
6
8
10
12
Sph S1P
0
20
40
60
80
GlcCer C24:0
**
*
0
5
10
15
20
25
30
35
Cer C24
A B
C D E
0
500
1000
1500
2000
2500
3000
3500
4000
iNPH
AD
SM
0
10
20
30
40
50
60
70
80
90
Total C16:0 C18:0 C22:0
dhSM
pm
ol
s/
m
g 
pr
ot
ei
n
pm
ol
s/
m
g 
pr
ot
ei
n
pm
ol
s/
m
g 
pr
ot
ei
n
pm
ol
s/
m
g 
pr
ot
ei
n
pm
ol
s/
m
g 
pr
ot
ei
n
Figure 3. LC-MS analysis sphingolipid levels in CSF from iNPH and AD patients. Total SMs (A) and dhSMs 
(B), as well as Cer C24:0 (C), tend to increase in AD patients compared to iNPH patients. S1P (D) decreased in 
AD compared to iNPH patients (t-test p-value < 0.05). GlcCer C24:0 (E) statistically increased in AD compared 
to iNPH patients (t-test p-value < 0.01).
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Figure 4. Immunoblot closeups (cropped images; full lenght blot is included as Supplementary Information) 
and histograms of protein expression levels are shown for neutral (nSMase) and acid Sphingomyelinase (ASM) 
in CSF from iNPH and AD patients. Both neutral and acid Sphingomyelinase tended to decrease in AD patients 
compared to iNPH controls. Ceramidase was not appreciably detected. Data were normalized against the total 
amount of loaded proteins stained with Sypro Ruby and reported as mean ± SD.
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Discussion
In the present study, variations of sphingolipid levels in CSF and serum were for the first time investigated in 
patients with iNPH. Our previous study demonstrated that patients with iNPH shares a CSF MALDI low molec-
ular weight protein profile similar to healthy controls and these patients can be considered a good reference for 
comparative study due to well matched physiological characteristics and the availability of CSF, routinely col-
lected for diagnosis and therapy compared to healthy subjects.
In the present study, the “sphingolipidome” analysis was performed combining different technologies to 
enlarge the data set of differentially expressed species. It is known that the use of different techniques adopting 
different separative steps (i.e. HPTLC vs HPLC) prior MS analysis and mass spectrometers (MALDI vs. LC-MS), 
allows to enlarge the data set of recognized species. In addition, due to the absence of an independent assay for 
data validation, being the use of antigen antibody detection hampered by mimicry exerted by antibodies24,25, the 
adoption of multiple technological approaches further supports the obtained semi quantitative data.
In serum, primuline staining after HPTLC indicated that both patients with iNPH and AD share the same 
increase of long chain and short chain Cers together with short chain SMs compared to controls. Blood sphin-
golipids may directly reflect brain and CSF SLs levels, due to the SLs crossing of the blood brain and of the 
blood-spinal cord barriers, or peripheral SLs may be associated with atherosclerosis, insulin resistance and diabe-
tes, all of which are known risk factors for AD26.
Results indicate that the pool of Cers and of long chain SMs species, belonging from different compartment 
and released in blood, are dysregulated both in patients with iNPH and AD, however, to decipher the contribution 
to neurodegeneration of specific chains and to highlight which, among other molecules, characterizes patients 
with iNPH and AD, a refined analysis of CSF was used.
The MALDI CSF profiling indicated a decrease of peaks at 766.58 m/z (Fig. 2A) and at 835.68 m/z, identified 
as SM C24:1, in AD patients compared to iNPH patients and controls, whereas peaks at 794.61 m/z, 796.59 m/z, 
808.61 m/z (identified as PC 36:2 [M + Na]+) and 830.61 m/z were statistically increased in patients with iNPH 
compared to AD (Fig. 1B–E). LC-MS analysis identified a set of SMs, not identified by MALDI, increased in 
patient with AD, together with a trend of increased levels of Cer C24:0. Importantly, in CSF, S1P levels were 
found statistically decreased in AD compared to iNPH affected patients, conversely GlcCer C24:0 was statistically 
increased in patients with AD.
Fonteh et al.27 described in CSF a decrease of total SM in CSF of AD patients compared to MCI and control 
subjects whereas Kosicek et al.28 identified in cognitive normal vs prodromal AD a significant increase of SMs 
in patients with AD (C14, C16, C20, C22 and C24 chains), and a non statistically significant decline of SMs in 
patients with mild to moderate AD compared to cognitively normal controls. However, the mechanism for SM 
increase in the prodromal phase of the disease is still unclear. Authors hypothesize that this early elevation of SMs 
in CSF of AD patients could result from an increased level of Cers utilized for SMs synthesis. Similarly, Mielke 
et al. found a correlation between sphingomyelin and Aβ values, total Tau and some forms of p-Tau in CSF of 
healthy individuals with parental history of AD29. In brain tissue, increased Cer levels and reduced SM concen-
trations were described in human gray matter of frontotemporal area in AD patients30–32. The increased levels of 
Cers, both in CSF and brain tissue, suggest a translocation of a-SMase to the plasma membrane leading to Cers 
over-production and SMs reduction33. Unfortunately, from our results, any apparent change has been reported for 
n-SMase33 indicating that the mechanism is more complex. It should also be considered that the concentration of 
most lipids in the human brain decrease after the age of 50. Phosphatidylinositol (PI), phosphatidylethanolamine 
Sphingosine Sphingosine
-1-P
Sphingomyelin
SM C24:1 
Ceramide
CerSs
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SphKs
CELL 
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Figure 5. Schematic results summary. Total SMs tend to increase in patients with AD compared to patients 
with iNPH, whereas SM C24:1 is significantly decreased; both the SMases (nSMase and ASM) result to be 
decreased, whereas Cer C24:0 tend to increase. Sphingosine-1-phosphate(S1P) is significantly reduced in AD 
compared to iNPH patients whereas glucosylceramide (GlcCer)C24:0 is augmented. Red arrows indicate a 
statistical significant result, whereas blue arrows indicate an increasing/decreasing trend.
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(PE) and phosphatidylcholine (PC) brain levels decrease very slowly with age, with less than 10% loss in the range 
of 40 to 100 years old34. A decrease of PC35,36 has been also reported in patients with AD. Interestingly, in the early 
stage of AD, brain levels of other phospholipid classes (PC, PI and PE) in both white and gray matter appeared 
to be unchanged37. Unchanged PC levels, but decreased lysoPC/PC ratio and elevation of different PC metabo-
lites have been reported in the CSF of AD patients compared to memory complaints non demented patients38 
suggesting an increased hydrolysis of PC in patients with AD39. Noteworthy, a number of studies described phos-
pholipid alterations in brains of AD patients, but only few studies described changes of this class of molecules 
in CSF and data provided by the present study on iNPH patients, are new. S1P is a protective molecule, favoring 
cell renewal and survival, produced by the action of ceramidase that enhances ceramide catabolism and for-
mation of its anti-apoptotic metabolite40. The latter is decreased in CSF from AD affected patients compared 
to iNPH patients indicating that the negative effects of ceramide accumulation cannot be prevented by S1P. To 
our knowledge, this is the first time that S1P decrement has been detected in CSF of AD patients41,42 since a 
decrement of S1P was described in the hippocampus and temporal cortex of AD human brain tissues, only42, 
providing further support to this molecule as putative biomarker of cognitive impairment. To establish the rela-
tionship between S1P decrement and AD, verification studies are currently ongoing. S1P-based signaling through 
S1P receptor 1 (S1PR1) rapidly and reversely reduces basal P-glycoprotein transport activity at the blood-brain 
and blood-spinal cord barriers and the S1P efflux from brain and spinal cord endothelial cells is mediated by 
the multidrug resistance-associated protein 1 (Mrp1, Abcc1)43. Furthermore, the activation of the proinflamma-
tory pathway (TNF-α), typical of AD, decreases the P-glycoprotein activity and it has been described that iNPH 
patients show higher levels of CSF TNF-α compared to MCI subjects44 leading to speculate on the role of SP1 as 
a possible marker for differential diagnosis but also in this case results are contradictory since other publications 
describe low45 or unchanged46 levels of TNF-α, suggesting that also in this case the inter individual variability 
plays a major role.
Another novelty introduced by this study is the increment of GlcCer C24:0 detected in the CSF of AD patients. 
This result can be directly associated to increased levels of Cer, a precursor of GlcCer. The GlcCer increment was 
not observed in patients with iNPH despite increased levels of Cers. It can be hypothesized that after the translo-
cation of a-SMase to the plasma membrane, that leads to Cer over-production and SM reduction, the higher levels 
of Cer stimulates the activity of ceramide glucosyltrasferase, accounting for increased GlcCer in AD.
Based on the present results, we wondered which was the contribution of GlcCer in this context. This mole-
cules has been recently described as associated to alpha synuclein misfolded tetramer formation in Parkinson’s 
disease (PD)47 suggesting that GLSs accumulation is sufficient to increase the susceptibility of neurons to cyto-
toxicity. Another recent paper by Friederike Zunke et al.48 highlighted the role of GlcCer accumulation in syn-
uclein conformers formation, however the increase of GlcCer and the GlcCer/GalCer ratio assessed in 26 PD 
patients with different disease stages by LC-MS/MS, indicated a trend not statistically significant, suggesting that 
the interindividual variability of these molecules is high and a number of other molecules should be associated 
to link their variation to disease progression49. In this context, the level of ApoA1proteoforms, described in our 
previous study as significantly decreased in AD compared to iNPH and controls could be good candidates to be 
assessed in association with increased levels of GlcCer in patients with AD. Further studies are ongoing to verify 
the association of ApoA1 and SLs dysregulation in MCI patients. The GlcCer accumulation, together with S1P 
decrement in AD can be associated to apoptosis of neuronal cells, not present in iNPH in which the mechanism 
of autophagy is probably maintained, studies are in progress on this direction. To contribute to shed light in the 
intricate picture of sphingolipids, the antigen-antibody detection of enzymes involved in Cer and SM metabolism 
indicated a decreased trend of acidic and neutral SMase supporting that increased levels of several species of SM, 
detected by LC-MS, could be associated to the decreased trend of these enzymes. Unfortunately for ceramidase, a 
faint band, not quantitable was detected in patients with iNPH only, whereas this band was absent in AD patients 
(data not shown). To detect this enzyme a larger sample loading not affordable with our CSF sample volume is 
needed, leaving this question still open. Beside the sample volume availability, another limitation of the present 
study is the number of available samples for verification studies in which a larger number of patients and controls 
are needed to precisely define the role of SLs and ApoA1 in AD as putative markers for AD diagnosis. Verification 
studies are in progress to confirm the increment of Cer, GlcCer and of same species of SM in patient with AD 
compared to patients with iNPH by MRM based MS analysis of CSF, in addition proteopetides of SMase and cer-
amidases will be quantitated adopting the same technological approach with the aim to build a multiple test able 
to contribute to better diagnosis of AD and iNPH syndromes.
In conclusion, as summarized in Fig. 5, the present results suggest that levels of Cers, S1P, SMs and GlcCer in 
CSF can contribute to the differential analysis of patients with iNPH vs. AD and can potentially be predictive to a 
co-morbidity of AD in iNPH patients.
Materials and Methods
Study participants and sample collection. Serum and CSF samples from age and sex-matched control 
subjects, patients with idiopathic normal pressure hydrocephalus (iNPH) disease, and patients with Alzheimer’s 
(AD) disease, were collected at the Geriatric Unit of the Policlinico Hospital in Milan, Italy. The present study 
conforms to the principles of Helsinki Declaration, and the study protocol received approval from the Ethical 
Committee of Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy. Informed consent was 
obtained from either patients or legal representatives. Data about their medical history, physical and neurological 
examination, neurocognitive evaluation (Mini-Mental State Examination), computed tomography or MRI scan, 
and screening laboratory tests consisting in the assessment of tau, phospho-tau (p-tau), and amyloid-β (Aβ) pro-
teins levels by ELISA (Innogenetics) were collected. AD patients fulfilled the Dubois et al. criteria50. The iNPH 
subjects were diagnosed according to International Guidelines by Relkin N10. Control subjects were likewise 
examined to exclude the presence of neurological and cognitive disorders. The samples were aliquoted into 0.5 mL 
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polypropylene storage tubes, and stored in a −80 °C freezer until analysis. Protein assays were performed using a 
bicinchoninic acid protein assay kit (Pierce Biotechnology, Inc., Rockford, IL, USA) with bovine serum albumin 
as a standard.
Reagents/Chemical. Methanol, ethanol, HPLC-analytical grade chloroform (CHCl3), LC-MS 
grade water and LC-MS grade acetonitrile (ACN), acetone, 2,5-dihydroxybenzoic acid (DHB) matrix, 
3,5-Di-tert-4-butylhydroxytoluene (BHT) and primuline dye were from Sigma-Aldrich (Saint Louis, 
MO, USA). 1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC), Cardiolipin (Heart, Bovine), 
1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE), Ceramide d18:1 C16:0 and Cer d18:1 C24:0 stand-
ards were from Avanti Polar Lipids (Alabaster, Alabama, USA). Sphingolipid mixture (containing Sphingomyelin, 
Sulfatides and Cerebrosides-HexCers-), Neutral Glycosphingolipid Mixture (including Globoside -Gb4Cer-, 
Ceramide trihexoside -Gb3Cer-, LactosylCeramide -LacCer- and HexCers), Monosialoganglioside mixture (con-
taining GM1, GM2 and GM3) and Disialoganglioside mixture (containing GD1a, GD1b and GD3) were from 
Matreya LLC (Pleasant Gap, PA, USA).
Lipid extraction. Lipids were extracted from serum according to the procedure of Zahir H. Alshehry et al.51. 
Serum aliquots of 100 µL were mixed with 1 ml of methanol/buthanol 1:1 (v/v) containing ammonium formate 
5 mM. Mixtures were vortexed for 10 seconds, sonicated for 1 hour in a sonic water bath (20 °C) and centrifuged 
for 10 minutes at 16000 g (20 °C). Liquid phases were collected and transferred in borosilicate glass vials with 
Teflon-lined caps (VWR, Radnor, PA) and, after nitrogen-flux drying, re-suspended in 150 μL of chloroform/
methanol 2:1 (v/v) containing BHT 0.01% (w/v) and stored at −20 °C. Total protein content was determined, 
according to manufacturer’s instructions, for each sample prior to lipid extraction, using Pierce™ BCA Protein 
Assay Kit (Pierce Biotechnology, Inc., Rockford, IL, USA).
CSF lipids were extracted using a modified Bligh and Dyer procedure29. Briefly, 100 µl of CSF were mixed with 
300 µl of methanol containing ammonium formate (53 mM) and BHT 0.01% weight/volume (w/v). After mixture 
vortexing, 400 µL of chloroform were added. The mixture was centrifuged at 2000 g for 15 minutes. The chloro-
form layer was carefully removed and dried in a nitrogen evaporator. The lipid content was normalized in relation 
to total protein content and dried extracts were resuspended in a volume of 1 µL of chloroform/methanol (2:1, 
v/v) per µg protein and stored in borosilicate glass vials with Teflon-lined caps (VWR, Radnor, PA).
HPTLC-Primuline. Aluminium backed HPTLC silica plates 200 × 100 mm (MERK, Billerica, Massachusetts), 
were initially developed in chloroform/methanol 1:1 (v/v), and dried at 120 °C for 20 minutes. Each sample 
(100 µg of total protein) was loaded in duplicate on HPTLC plates using Linomat 5 semiautomatic TLC spotter 
(CAMAG, Switzerland) (lane width: 6 mm, dosage speed: 150nL/s). Two different standard mixtures were loaded 
on HPTLC plates lateral edges. First mixture consisted of SM, GlcCer, Cer C16 and C24 standards; the second 
one was made of DPPE and DPPC. After loading, HPTLC plates were developed in chloroform/methanol/water 
55:20:3 (v/v/v), using Automatic Developing Chamber 2 (CAMAG, Switzerland) with settings as follows: plate 
size 20 × 10 cm, pre-drying, control humidity 3 minutes, saturation time 20 minutes, plate preconditioning time 
1 minute, migration distance 65 mm and drying time 1 minute. Developed plates were sprayed with a solution of 
primuline yellow dye, 5 mg/100 ml in propan-2-one/water 80:20 (v/v) and dried under a fume hood. Images from 
primuline-stained plates were acquired using Ettan DIGE Imager (GE Healthcare, Chicago, IL, USA). Imager 
settings were: pixel size 100 µm, excitation filter 480/30, emission filter 592/25. Acquired images were analyzed 
using ImageQuant software v.8.1 (GE Healthcare, Chicago, IL, USA) setting as follows: manual lane selection, 
rolling ball baseline subtraction and automatic band detection. Data were exported in Excel format. Excel data 
were analyzed using the software SigmaStat v.3.5 build.3.5.0.74 (Systat Software Inc., California, USA).
CSF MALDI Profiling. 0.5 µL of 2,5 dihydroxybenzoic acid (DHB) matrix at 20 mg/ml in 70% acetonitrile 
were loaded on Anchorchip target (600–384 target, Bruker Daltonics) and 0.5 µl of organic phases obtained from 
lipid extraction and drying of CSF samples, were spotted in four replicates on the matrix layer. A calibration solu-
tion was prepared by mixing PC, ceramides and cardiolipin standards, and loaded on calibration spots, with the 
same procedure followed for samples. The mixture was let to dry at room temperature. Spectra were acquired in 
reflectron positive modality using an Ultraflex III mass spectrometer equipped with Smartbeam laser (frequency 
of 100 Hz, Bruker Daltonics), Flex Control software v. 3.3, and Flex Analysis software v.3.3 (Bruker Daltonics). 
The spectrometer settings were: ion source 1, 25 kV; ion source 2, 21.67 kV; lens, 9.3 kV; reflector 26.3 kV; reflec-
tor 2 13.7 kV; mass suppression up to m/z 200; detector gain voltage, 1645 V; electronic gain, 100 mV/full scale. 
Spectra were collected using an automatic software, AutoXecute (Bruker Daltonics), whose parameters were the 
following: fuzzy control, off; laser power, 60%; total laser shots, 1000; random walk movement (20 shots per 
raster spot). CSF profiling mass spectra were analyzed by ClinProTools software v.2.2 (Bruker Daltonics) using 
the following spectra preparation parameters: 18000 resolution, Top Hat Baseline, 7% minimal baseline width, 
Savitsky–Golay smoothing.
ClinProTools’ statistics was performed by Wilcoxon’s t-test (2 classes) or Kruskal-Wallis test (>2 classes) 
through which a list of best separating peaks (p-value < 0.01) was generated.
Best separating peaks identification. Ions of interest were subjected to MALDI-TOF/TOF for struc-
ture determination and eventual identification. Mass signal of parent ions were isolated and fragmented in LIFT 
operation mode. The nomenclature introduced by Domon and Costello52 and Adams and Ann53 was used for the 
assignment of the fragments ions. NIST MS Search v 2.2 software was used as a support for peaks identification: 
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MS/MS spectra were loaded in the software and compared with those included in NIST/EPA/NIH Mass Spectral 
Library (NIST 14) and in LipidBlast Library54.
To confirm the identification of sphingomyelin, the organic phase was submitted to an alkaline treatment 
to remove glycerophospholipids. Briefly, it was resuspended in 100 µL of CHCl3 and 100 µL of 0.6 N NaOH in 
methanol and allowed to stand at 37 °C for 2 hours. The reaction was blocked by adding 120 µL of 0.5 M HCl in 
methanol. The sample was then submitted to another phase separation and the new organic phase was loaded on 
an Anchorchip target for spectra acquisition.
LC-MS analysis. For LC-MS analysis, sera were randomly sub-pooled into 3 groups of iNPH and 3 of 
AD CSF samples. The sub-pooling was adopted as a method to reduce the variance among biological groups 
increasing the power to detect changes when few samples are available and the variance is high55,56. Sphingolipid 
extracts were analysed in presence of N-lauroyl-D-erythro-sphingosine, N-lauroyl-D-erythro-sphinganine, 
N-lauroyl-D-erythro-sphingosylphosphorylcholine N-lauroyl-D-erythro-sphinganylphosphorylcholine, 
D-glucosyl-ß−1,1′-N-lauroyl-D-erythro-sphingosine, D-lactosyl-ß-1,1′ N-lauroyl-D-erythro-sphingosine and 
C17 d-erythro-dihydrosphingosine-1-phosphate (0.5 nmol each, as internal standards, prepared as described 
by Merrill et al.57 and analysed by Waters Aquity UPLC system connected to a Waters LCT Premier orthogonal 
accelerated time of flight mass spectrometer (Waters, Millford, MA), operating in positive electrospray ionisation 
mode. Full scan spectra were acquired from 50 to 1500 Da, and individual spectra were summed to produce data 
points each 0.2 s. Mass accuracy and reproducibility were maintained by using an independent reference spray 
by the LockSpray interference. C8 Acquity UPLC BEH (Waters), 100 mm length, 2.1 mm outer diameter, i.d., 
1.7 mm, analytical column was employed. Mobile phase A: methanol/water/formic acid (74/25/1 v/v/v); mobile 
phase B: methanol/formic acid (99/1 v/v), both containing 5 mM ammonium formate. A linear gradient was pro-
grammed—0.0 min: 80% B; 3 min: 90% B; 6 min: 90% B; 15 min: 99% B;18 min: 99% B; 20 min: 80% B. The flow 
rate was 0.3 mL/min. The column was kept at 30 °C.
Quantification was carried out using the extracted ion chromatogram of each compound, in a 50 mDa 
windows. The linear dynamic range was determined by injecting standard mixtures. Positive identification of 
compounds was based on the accurate mass measurement with an error <5 ppm and its LC retention time, 
compared to that of a standard (±2%). Mass spectra were analyzed by MassLynx™ 4.1 Software and data were 
compared performing unpaired two-tailed Student’s t test, p-value < 0.05 using SigmaStat v.3.5 build.3.5.0.74 
(Systat Software Inc., California, USA).
Western blot analysis. Prior to SDS page analysis, CSF total protein content was determined using Pierce 
BCA protein assay Kit. Sera were randomly sub-pooled into two groups for iNPH and two groups for AD, each 
one constituted of 3 different samples. The protein content of the pooled CSF samples ranged from 0.5822 μg/μl 
to 1.204 μg/μl. 80 µg of CSF total proteins from each different sub-pool were separated in duplicate by sodium 
dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE), transferred and blocked onto a polyvi-
nylidene fluoride (PVDF) membrane (300 mA, 180 min) utilizing a Transblot Cell from GE Healthcare (Uppsala, 
Sweden). The membrane was blocked overnight in tris-buffered saline (TBS) (20 mM Tris, 137 mM NaCl, 0.1% 
Tween, pH 7.5) containing 5% bovine serum albumin (Sigma Aldrich, Saint Louis, MO, USA) and incubated 
with the following primary antibodies: anti-ASM 1:500 (Santa Cruz Biotechnology, sc-9817, Dallas, MO, USA), 
anti-nSMase 1:1000 (Abcam, ab-131330, Cambridge, UK) and anti- ASAH2 1:1000 (SigmaAldrich, PRS4743). 
Anti-goat (Santa Cruz Biotechnology, 1:5000) was used as secondary antibody for ASM, whereas anti-rabbit (GE 
Healthcare,1:10000) was used for nSMase and ASAH2. Proteins were visualized by chemiluminescence (ECL 
Prime kit, GE Healthcare). Band intensities were detected using an Image Quant LAS 4000 mini imager (GE 
Healthcare) and assessed with the Image Quant TL 8.1 analysis software (GE Healthcare). Data were normalized 
against the total amount of proteins stained by Sypro Ruby and Student’s t-test by comparing AD and iNPH. 
Differences were considered significant at p-value < 0.05.
Data Availability
The data generated during and/or analysed during the current study are included in this published article (and 
its Supplementary Information files). When needed, further information are available from the corresponding 
author on reasonable request.
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